WO2017142368A3 - Composition for preventing and treating allergic or inflammatory skin disease - Google Patents

Composition for preventing and treating allergic or inflammatory skin disease Download PDF

Info

Publication number
WO2017142368A3
WO2017142368A3 PCT/KR2017/001808 KR2017001808W WO2017142368A3 WO 2017142368 A3 WO2017142368 A3 WO 2017142368A3 KR 2017001808 W KR2017001808 W KR 2017001808W WO 2017142368 A3 WO2017142368 A3 WO 2017142368A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
composition
inflammatory skin
treating allergic
skin disease
Prior art date
Application number
PCT/KR2017/001808
Other languages
French (fr)
Korean (ko)
Other versions
WO2017142368A2 (en
Inventor
한명관
오유근
Original Assignee
전북대학교 산학협력단
주식회사 스템디알
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 전북대학교 산학협력단, 주식회사 스템디알 filed Critical 전북대학교 산학협력단
Priority claimed from KR1020170021592A external-priority patent/KR20170098182A/en
Publication of WO2017142368A2 publication Critical patent/WO2017142368A2/en
Publication of WO2017142368A3 publication Critical patent/WO2017142368A3/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a composition for preventing or treating allergic or inflammatory disease, comprising an NED19, bromo-cyclic ADP-ribose or emodin as an effective ingredient. The NED19, bromo-cyclic ADP-ribose and emodin of the present invention have an excellent effect in preventing and treating various allergic or inflammatory skin diseases including histamine-dependent and histamine-independent itching and atopic dermatitis itching, and thus can be variously used in medicines, external skin preparations, foods, cosmetics, and the like.
PCT/KR2017/001808 2016-02-19 2017-02-17 Composition for preventing and treating allergic or inflammatory skin disease WO2017142368A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20160019807 2016-02-19
KR10-2016-0019807 2016-02-19
KR1020170021592A KR20170098182A (en) 2016-02-19 2017-02-17 Composition for preventing or treating allergic or inflammatory skin disease
KR10-2017-0021592 2017-02-17

Publications (2)

Publication Number Publication Date
WO2017142368A2 WO2017142368A2 (en) 2017-08-24
WO2017142368A3 true WO2017142368A3 (en) 2018-09-07

Family

ID=59625237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/001808 WO2017142368A2 (en) 2016-02-19 2017-02-17 Composition for preventing and treating allergic or inflammatory skin disease

Country Status (1)

Country Link
WO (1) WO2017142368A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3527227A4 (en) * 2016-10-11 2020-09-16 Industrial Cooperation Foundation Chonbuk National University Use of cadpr or naadp antagonists
CN116747213A (en) * 2023-06-30 2023-09-15 大连医科大学附属第一医院 Application of emodin in inhibiting sebaceous gland synthesis and secretion

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037089A1 (en) * 1998-12-18 2000-06-29 University Of Bath Cyclic adenosine diphosphate ribose analogues for modulating t cell activity
KR100812596B1 (en) * 2006-12-15 2008-03-13 바이오스펙트럼 주식회사 Compositions comprising compounds of natural origin for damaged skin
KR100832332B1 (en) * 2007-02-12 2008-05-26 바이오스펙트럼 주식회사 Compositions for ameliorating symptom of atopic dermatitis
WO2009156724A2 (en) * 2008-06-25 2009-12-30 Isis Innovation Limited Novel compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037089A1 (en) * 1998-12-18 2000-06-29 University Of Bath Cyclic adenosine diphosphate ribose analogues for modulating t cell activity
KR100812596B1 (en) * 2006-12-15 2008-03-13 바이오스펙트럼 주식회사 Compositions comprising compounds of natural origin for damaged skin
KR100832332B1 (en) * 2007-02-12 2008-05-26 바이오스펙트럼 주식회사 Compositions for ameliorating symptom of atopic dermatitis
WO2009156724A2 (en) * 2008-06-25 2009-12-30 Isis Innovation Limited Novel compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LU: "Emodin, a naturally occurring anthraquinone derivative, suppresses IgE-mediated anaphylactic reaction and mast cell activation", BIOCHEMICAL PHARMACOLOGY, vol. 82, 2011, pages 1700 - 1708, XP028329281, DOI: doi:10.1016/j.bcp.2011.08.022 *
WANG WEIMIN ET AL.: "Anti-allergic activity of emodin on IgE-mediated activation in RBL-2H3 cells", PHARMACOLOGICAL REPORTS, vol. 64, 2012, pages 1216 - 1222, XP055601330, ISSN: 1734-1140 *

Also Published As

Publication number Publication date
WO2017142368A2 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
IL255203B (en) Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders
WO2016172658A3 (en) Microbiome regulators and related uses thereof
EP3684353A4 (en) Topical formulations of cannabinoids and use thereof in the treatment of pain
EP3668497A4 (en) Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response
EP4219713A3 (en) Products and compositions
WO2015073587A3 (en) Synthetic membrane-receiver complexes
WO2017207481A8 (en) Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
SI3377637T1 (en) Compositions for use in methods for the treatment of wounds, disorders, and diseases of the skin
WO2015077503A8 (en) Autotaxin inhibitor compounds
EP3483256A4 (en) Akkermansia muciniphila strain having effect of preventing or treating degenerative brain diseases or metabolic diseases, and use thereof
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
PH12017500706A1 (en) Composition containing extract or fraction of genus justicia plant
AU2018264384A1 (en) Solid forms of berberine ursodeoxycholate and compositions and methods thereof
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
MX370958B (en) Use of alkylamidothiazoles in cosmetic or dermatological preparations for the prophylaxis or treatment of sensitive skin.
EP3582768A4 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
MX2018008645A (en) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2015106215A3 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2017142368A3 (en) Composition for preventing and treating allergic or inflammatory skin disease
WO2013153108A3 (en) Embelia concinna extract comprising flavonoids in cosmetic and pharmaceutical compositions
WO2018081183A3 (en) Maca compositions and methods of use

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17753529

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17753529

Country of ref document: EP

Kind code of ref document: A2